Shield Therapeutics (AIM: STX)

Last close As at 21/12/2024

GBP0.02

−0.05 (−3.16%)

Market capitalisation

13m

Edison Investment Research is terminating coverage on Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Flash note

Shield Therapeutics — New CFO to support US traction

Healthcare | Flash note

Shield Therapeutics — Delivering what the doctor ordered

Healthcare | Update

Shield Therapeutics — FY23 a key year for business traction

Laboratory

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free